[Vaccination with human "papillomavirus-like particles"].
Funk
J O
JO
Oncology Research Darmstadt, Global Preclinical R&D, Merck KGaA.
D000914:Antibodies, Viral / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D014565:Urogenital Neoplasms / Q000276:immunology / Q000517:prevention & control*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control*; D022721:Vaccines, Virosome / Q000008:administration & dosage / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D022721:Vaccines, Virosome; D014765:Viral Vaccines